Ray Dalio Neurocrine Biosciences Inc Transaction History

Bridgewater Associates, LP

$17.3 Billion
Q3 2024

A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Bridgewater Associates, LP holds 135,186 shares of NBIX stock, worth $18.9 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

135,186

Previous 87,548 54.41%

Holding current value

$18.9 Million

Previous $12.1 Million 29.13%

% of portfolio

0.09%

Previous 0.06%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$114.58 - $153.15 $5.46 Million - $7.3 Million	47,638 Added 54.41%	135,186 $15.6 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $8.43 Million - $9.22 Million	64,397 Added 278.16%	87,548 $12.1 Million
Q1 2024 May 14, 2024	SELL	$130.4 - $143.74 $46,161 - $50,883	-354 Reduced 1.51%	23,151 $3.19 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $3.34 Million - $4.18 Million	-31,490 Reduced 57.26%	23,505 $3.1 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $15,983 - $19,907	-170 Reduced 0.31%	54,995 $6.19 Million
Q2 2023 Aug 11, 2023	SELL	$89.53 - $104.87 $362,148 - $424,199	-4,045 Reduced 6.83%	55,165 $5.2 Million
Q1 2023 May 12, 2023	BUY	$94.11 - $123.02 $5.57 Million - $7.28 Million	59,210 New	59,210 $5.99 Million
Q2 2022 Aug 11, 2022	BUY	$75.79 - $100.07 $112,396 - $148,403	1,483 Added 29.54%	6,503 $634,000
Q1 2022 May 13, 2022	BUY	$72.45 - $94.81 $180,617 - $236,361	2,493 Added 98.65%	5,020 $471,000
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $53,365 - $71,167	-670 Reduced 20.96%	2,527 $215,000
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $235,874 - $271,045	-2,737 Reduced 46.12%	3,197 $307,000
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $530,677 - $606,870	5,934 New	5,934 $577,000

Others Institutions Holding NBIX

# of Institutions

626

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.3B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track Ray Dalio's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.

Account